Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults

Expert Review of Clinical Pharmacology

Volumn 7, Issue 3, 2014, Pages 327-340

  Gostelow, Martyn ^a   Gonzalez, Daniel ^a,b   Smith, P Brian ^a   Cohen Wolkowiez, Michael ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Ceftaroline; Dalfopristin; Daptomycin; Linezolid; Neonate; Quinupristin; Sepsis; Tigecycline

Indexed keywords

CEFTAROLINE; CEFTRIAXONE; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; TELAVANCIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT DISEASE; ANUS FISTULA; ARTHRALGIA; BACTERICIDAL ACTIVITY; BINDING AFFINITY; CANDIDIASIS; CELL MEMBRANE POTENTIAL; CHILDHOOD DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; CONVULSION; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; EXTRACELLULAR FLUID; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INFANT DISEASE; INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; KIDNEY DISEASE; MACULOPAPULAR RASH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MYALGIA; NAUSEA; PEDIATRICS; PERIPHERAL EDEMA; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN PAIN; SKIN STRUCTURE; SURGICAL INFECTION; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING; ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFECTS; INFANT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; PRESCHOOL CHILD; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; INFANT; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898908150     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.909281     Document Type: Review

References (93)

1. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a metaanalysis. Clin Infect Dis 2003;36(1):53-9
2. Song X, Perencevich E, Campos J, et al. Clinical and economic impact of methicillin-resistant Staphylococcus aureus colonization or infection on neonates in intensive care units. Infect Control Hosp Epidemiol 2010;31(2):177-82
3. Dantes R, Mu Y, Belflower R, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections. United States, 2011. JAMA Intern Med 2013;173(21):1970-8
4. Herigon JC, Hersh AL, Gerber JS, et al. Antibiotic management of Staphylococcus aureus infections in US children's hospitals, 1999-2008. Pediatrics 2010;125(6): e1294-300
5. Iwamoto M, Mu Y, Lynfield R, et al. Trends in invasive methicillin-resistant Staphylococcus aureus infections. Pediatrics 2013;132(4):e817-24
6. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-55
7. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349(12):1157-67
8. DailyMed. U.S. National Library of Medicine, Bethesda, MD, 2013. Available from: http://dailymed.nlm.nih.gov/
9. Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 1997;41(10):2127-31
10. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42(12):3251-5
11. Pharmacia and Upjohn Company. (2013). Zyvox (linezolid), package insert. Kalamazoo, MI, USA
12. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40(4):839-45
13. Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos 2001;22(3):91-7
14. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003;42(13):1129-40
15. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003;51(5):1239-46
16. Leach KL, Brickner SJ, Noe MC, Miller PF. Linezolid, the first oxazolidinone antibacterial agent. Ann N Y Acad Sci 2011;1222:49-54
17. Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos 2001;29(8): 1136-45
18. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003;22(9 Suppl):S153-7
19. Wible K, Tregnaghi M, Bruss J, et al. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr Infect Dis J 2003;22(4): 315-23
20. Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant gram-positive infections in children. Pediatr Infect Dis J 2003;22(8): 677-86
21. Deville JG, Adler S, Azimi PH, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 2003;22(9 Suppl):S158-63
22. Cubist Pharmaceuticals Inc. (2013). Cubicin (daptomycin), package insert. Lexington, MA, USA
23. Oberholzer CM, Caserta MT. Antimicrobial update: daptomycin. Pediatr Infect Dis J 2005;24(10):919-20
24. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections. J Antimicrob Chemother 2005;55(3):283-8
25. Critchley IA, Draghi DC, Sahm DF, et al. Activity of daptomycin against susceptible and multidrug-resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 2003;51(3):639-49
26. Dvorchik B, Damphousse D. Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J Clin Pharmacol 2004;44(6):612-20
27. Dvorchik B, Arbeit RD, Chung J, et al. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004;48(8):2799-807
28. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50(10):3245-9
29. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47(4):1318-23
30. Liang SH, Sheng WH, Huang YT, et al. Pharmacokinetics and safety of multiple intravenous doses of daptomycin in a Taiwanese adult population. Chemotherapy 2009;55(2):91-6
31. Abdel-Rahman SM, Benziger DP, Jacobs RF, et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 2008;27(4): 330-4
32. Cohen-Wolkowiez M, Watt KM, Hornik CP, et al. Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr Infect Dis J 2012; 31(9):935-7
33. Cohen-Wolkowiez M, Smith PB, Benjamin DK Jr, et al. Daptomycin use in infants: report of two cases with peak and trough drug concentrations. J Perinatol 2008;28(3):233-4
34. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38(12):1673-81
35. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355(7):653-65
36. Ardura MI, Mejias A, Katz KS, et al. Daptomycin therapy for invasive gram-positive bacterial infections in children. Pediatr Infect Dis J 2007;26(12): 1128-32
37. Antachopoulos C, Iosifidis E, Sarafidis K, et al. Serum levels of daptomycin in pediatric patients. Infection 2012;40(4): 367-71
38. ClinicalTrials.gov. U.S. National Institutes of Health, Silver Spring, MD, 2013. Available from: http://clinicaltrials.gov
39. Pfizer Laboratories. (2013). Synercid (quinupristin and dalfopristin injection), package insert. New York, NY, USA
40. Cocito C, Di Giambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997;39(Suppl A): 7-13.
41. Gaillad C VCJ, Montay G, et al. Disposition of the radiolabelled streptogramin RP 59500 in healthy male volunteers. Presented at: 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, USA; 1992
42. Bergeron M, Montay G. The pharmacokinetics of quinupristin/ dalfopristin in laboratory animals and in humans. J Antimicrob Chemother 1997; 39(Suppl A):129-38
43. Chevalier P, Rey J, Pasquier O, et al. Multiple-dose pharmacokinetics and safety of two regimens of quinupristin/dalfopristin (Synercid) in healthy volunteers. J Clin Pharmacol 2001;41(4):404-14
44. Chevalier P, Rey J, Pasquier O, et al. Pharmacokinetics of quinupristin/ dalfopristin in patients with severe chronic renal insufficiency. Clin Pharmacokinet 2000;39(1):77-84
45. Chevalier PR, Boucher E, et al. Open, comparative, study of the pharmacokinetics and safety of a single dose of quinupristin/ dalfopristin (Q/D), RP 59500, Synercid) in subjects with hepatic cirrhosis and healthy volunteers. Presented at: 20th International Congress of Chemotherapy. Sydney, Australia; 1997
46. Lefebvre PR, Harding N, et al. Open, comparative study of the pharmacokinetic and safety of a single dose of quinupristin/ dalfopristin (Q/D, RP 59500, Synercid) in healthy elderly volunteers and healthy young volunteers. Presented at: 20th International Congress of Chemotherapy, Sydney, Australia; 1997
47. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/ dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999;44(2):263-73
48. Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999;44(2):251-61
49. Loeffler AM, Drew RH, Perfect JR, et al. Safety and efficacy of quinupristin/ dalfopristin for treatment of invasive gram-positive infections in pediatric patients. Pediatr Infect Dis J 2002;21(10): 950-6
50. Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161(3 Pt 1):753-62
51. Verma A, Dhawan A, Philpott-Howard J, et al. Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/dalfopristin. J Antimicrob Chemother 2001;47(1):105-8
52. Plotkin P, Patel K, Uminski A, Marzella N. Telavancin (vibativ), a new option for the treatment of gram-positive infections. P T 2011;36(3):127-38
53. Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49(3): 1127-34
54. Lunde CS, Hartouni SR, Janc JW, et al. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 2009; 53(8):3375-83
55. Krause KM, Renelli M, Difuntorum S, et al. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother 2008;52(7):2647-52
56. Mendes RE, Sader HS, Farrell DJ, Jones RN. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of gram-positive clinical pathogens from five continents. Antimicrob Agents Chemother 2012;56(7):3999-4004
57. Theravance. (2012). VIBATIV (telavancin hydrochloride), package insert. San Francisco, CA, USA
58. Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005;49(1):195-201
59. Barcia-Macay M, Mouaden F, Mingeot-Leclercq MP, et al. Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). J Antimicrob Chemother 2008;61(6):1288-94
60. Wong SL, Barriere SL, Kitt MM, Goldberg MR. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 2008;62(4):780-3
61. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50(3):862-7
62. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46(11):1683-93
63. Barriere SL. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future Microbiol 2010;5(12): 1765-73
64. Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011;52(1):31-40
65. Biek D, Critchley IA, Riccobene TA, Thye DA. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-gram-positive activity. J Antimicrob Chemother 2010;65(Suppl 4): iv9-16
66. Sader HS, Fritsche TR, Kaniga K, et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005;49(8):3501-12
67. Jones RN, Fritsche TR, Ge Y, et al. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005;56(6):1047-52
68. Forest Laboratories. (2013). Teflaro (ceftaroline fosamil), package insert. St. Louis, MO, USA
69. Riccobene TA, Su SF, Rank D. Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Antimicrob Agents Chemother 2013;57(3):1496-504
70. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51(10):3612-16
71. Corey GR, Wilcox MH, Talbot GH, et al. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65(Suppl 4):iv41-51
72. Wilcox MH, Corey GR, Talbot GH, et al. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010;65(Suppl 4):iv53-65
73. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010;51(6):641-50
74. File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66(Suppl 3):III19-32
75. Low DE, File TM Jr, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66(Suppl 3):III33-44
76. Olson MW, Ruzin A, Feyfant E, et al. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother 2006;50(6): 2156-66
77. Wyeth Pharmaceuticals. (2013). Tygacil (tigecycline injection), package insert. Philadelphia, PA, USA
78. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000;20(9 Pt 2): 219S-23S; discussion 224S-228S
79. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000;44(8):2225-9
80. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49(1):220-9
81. Muralidharan G, Fruncillo RJ, Micalizzi M, et al. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005;49(4):1656-9
82. Meagher AK, Passarell JA, Cirincione BB, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007;51(6):1939-45
83. Purdy J, Jouve S, Yan JL, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther 2012;34(2):496-507; e491
84. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008;62(Suppl 1):i17-28
85. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5):S341-53
86. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012;54(12):1699-709
87. Purdy J, Jouve S, Yan JL, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther 2012;34(2):496-507; e491
88. Laughon MM, Benjamin DK Jr, Capparelli EV, et al. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol 2011;4(5):643-52
89. Capparelli E, Hochwald C, Rasmussen M, et al. Population pharmacokinetics of cefepime in the neonate. Antimicrob Agents Chemother 2005;49(7):2760-6
90. Wade KC, Wu D, Kaufman DA, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008;52(11):4043-9
91. Pullen J, Stolk LM, Nieman FH, et al. Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates. Ther Drug Monit 2006;28(2):226-31
92. Novel antibiotics pipeline. BioCentury Publications, Redwood City, CA, 2014. Available from: http://biocentury/ antibioticspipeline/htm
93. Pediatric Research Equity Act. 108th Congress of the United States of America, 3 December 2003: Statute 117-1936-1943